we only need to repeat the (pre specified) results we achieved in the first rct to achieve eua in under 65, how is that an issue.
what i also found interesting apart from the survival rates and new trial partner is how the rationale for extended dosing in older patients can be drawn from gvhd. with an already established extended dosing regimen of 8 doses over 4 weeks, if ards patients get this many doses and then recover it will be something.
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients, page-21
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.0¢ |
Change
-0.005(0.54%) |
Mkt cap ! $1.053B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 92.5¢ | 91.5¢ | $1.133M | 1.233M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 151980 | 91.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 29989 | 2 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |